Tuesday , August 14 2018
Home / Letter From The Editor / Letter from the Editor #678

Letter from the Editor #678

May 23, 2013

We are at a point with oral medications for diabetes where there are new drug approvals in recently approved classes, new drug classes where the first in class is approved, as well as late trial research moving quickly for drugs in yet unapproved classes. First it was the DPP-4 inhibitors with Januvia, Onglyza, Tradjenta and Nesina. Next was Cycloset and the new SGLT2-inhibitor, Invokana, recently approved as first in class. Now there is a class called GPR40-agonists of which fasiglifam, from Takeda, is the first to get far enough along in phase 3 trials to garner some interest.

GPR40 receptors appear to be closely involved in the pathology of various metabolic disorders including obesity, dyslipidemia, and type 2 diabetes, and could offer yet another drug class in the diabetes arsenal.

However with all these new classes and drugs one has to wonder if any of them will reach the blockbuster status that Januvia reached. According to Dr. Valentina Gburcik, Cardiovascular & Metabolic Disorders Analyst for the research and consulting firm, GlobalData, "While Takeda’s new drug shows promise, the lack of treatments tackling the condition’s root cause may result in the underwhelming market performance of individual drugs." She goes on to say, "We are entering an era in the diabetes market where the first-in-class drugs start in many ways to resemble ‘me-too’ drugs, despite their novel mechanisms of action. With some of the diabetes drugs going off patent, the prospect for future diabetes blockbusters becomes even bleaker due to eventual generic competition to the former blockbusters, and consequently, even more pronounced cost-effectiveness issues."

Speaking of root causes, research on a common gut bacteria could lead to new ways to improve metabolic processes to control obesity and type 2 diabetes


Topics: Charlie O’Connell talks about exercise and the Dawn Phenomenon; Chef Michel Nischan cooks up some grilled shrimp and eggplant; Jim Turner talks with other people living with diabetes about how every day is tough; Golfer Michelle McGann shares her experience with living with diabetes. Sundays live online at dLifeTV.com at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at dLifeTV.com.


Please answer this week’s poll: Should a person newly diagnosed with prediabetes be treated with medication along with lifestyle changes?
We can make a difference!

Dave Joffe, Editor-in-chief